Genprex (NASDAQ:GNPX) is a clinical-stage gene therapy company deeply rooted in developing treatments for cancer and diabetes. Through groundbreaking research and innovative technology, Genprex is on the forefront of creating gene therapies that could potentially transform patient outcomes. The company's operations are focused on advancing its proprietary platform technologies, including Oncoprex™ immunogene therapy for non-small cell lung cancer. A pivotal part of their mission is to leap beyond traditional treatments, harnessing the power of gene therapy to unlock new possibilities for patients around the globe. With a passionate commitment to science and health, Genprex aims to achieve significant milestones in medicine and offer new hope to individuals battling these complex diseases.